Rheumatoid Arthritis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for rheumatoid arthritis. 235 active patents protecting 11 drugs from 6+ originators. First major cliff: 2030. Daily refresh.

11
Approved drugs
235
Active US patents
61/100
Avg vulnerability
$3.1B
Annual revenue covered

Originators in Rheumatoid Arthritis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Boehringer Ingelheim 97 patents Generic (originally Schering) 47 patents Pfizer Inc. (originally Searle/Pharmacia) 37 patents Novartis AG (originally Sandoz) 17 patents Eli Lilly 17 patents Hisamitsu Pharmaceutical Co., Inc 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating rheumatoid arthritis. Each bar = one year. Y-axis scaled to peak year (82 patents).

18
27
3
28
20
29
38
30
8
31
19
32
9
33
9
34
4
35
82
36
6
37
4
38
4
39
4
40
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Mobic
MELOXICAM
 Boehringer Ingelheim 97 59 — 2030-05-26
Arthrotec
Diclofenac Sodium
 Pfizer 24 73 — 2027-03-22
Sandimmune
cyclosporine
 Novartis AG (originally Sandoz) 17 55 $1.9B 2027-11-03
Olumiant
baricitinib
 Eli Lilly 17 62 $1.2B 2029-03-10
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Voltaren
DICLOFENAC
 Hisamitsu Pharmaceutical Co., Inc 14 57 — 2030-04-23
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Advil
ibuprofen
 Generic (originally Boots Group) 14 70 — 2029-09-30
Celebrex
celecoxib
 Pfizer Inc. (originally Searle/Pharmacia) 13 51 — 2030-04-19
Indocin Sr
INDOMETHACIN
 — 6 56 — 2030-04-23
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8946292 Arthrotec method of use 80 2027-03-22
8871809 Arthrotec method of use 80 2027-10-17
8563613 Arthrotec method of use 80 2027-10-17
8168218 Deltasone method of use 80 2028-01-07
8252838 Arthrotec method of use 80 2028-04-21
11478488 Celebrex method of use 76 2030-04-19
11806555 Olumiant method of use 76 2031-11-02
9737469 Olumiant method of use 76 2031-11-02
11806555 Olumiant method of use 76 2031-11-02
11806555 Olumiant method of use 76 2031-11-02

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8158616 Olumiant composition of matter 4 2032-05-31
8158616 Olumiant composition of matter 4 2032-05-31
12059423 Mobic composition of matter 5 2040-07-19
10245276 Celebrex composition of matter 10 2030-04-19
8598152 Celebrex composition of matter 10 2030-04-19
9012440 Celebrex composition of matter 10 2030-04-19
8158616 Olumiant composition of matter 12 2032-05-31
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
9649318 Mobic formulation 30 2035-03-31

Related